Home > About Us > Leadership
mail print

The Company is led by a multidisciplinary team with significant experience in pharmaceutical product development and commercialization.


Clive A. Meanwell, MD, PhD
Chairman and Chief Executive Officer

Clive A. Meanwell has been a director since 1996. He has served as our chief executive officer since February 2012, our chief executive officer and president from October 2009 to February 2012, as our chief executive officer from August 2004 to October 2009, as our president from August 2004 to December 2004, our executive chairman from September 2001 to August 2004 and as our chief executive officer and president from 1996 to September 2001. From 1995 to 1996, Dr. Meanwell was a partner and managing director at MPM Capital, L.P., a venture capital firm. From 1986 to 1995, Dr. Meanwell held various positions at Hoffmann-La Roche, Inc., a pharmaceutical company, including senior vice president from 1992 to 1995, vice president from 1991 to 1992 and director of product development from 1986 to 1991. Dr. Meanwell received an M.D. and a Ph.D. from the University of Birmingham, United Kingdom.

Glenn P. Sblendorio, MBA
President and Chief Financial Officer

Glenn P. Sblendorio has been a director since July 2011 and has been our chief financial officer and president since February 2012.  From March 2006 to February 2012, he served as our chief financial officer and executive vice president. From November 2005 until he joined us, Mr. Sblendorio served as a consultant to a company in the pharmaceutical industry. Prior to joining us, Mr. Sblendorio was executive vice president and chief financial officer of Eyetech Pharmaceuticals, Inc. from February 2002 until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. From July 2000 to February 2002, Mr. Sblendorio served as our senior vice president of business development. From 1998 to July 2000, Mr. Sblendorio was the chief executive officer and managing director of MPM Capital Advisors, LLC, an investment bank specializing in healthcare related transactions. Mr. Sblendorio's pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc., a pharmaceutical company, in a variety of senior financial positions, including vice president, finance of Roche Molecular Systems and head of finance-controller for Amgen/Roche Europe. Mr. Sblendorio currently serves as a director of Amicus Therapeutics, Inc., a biopharmaceutical company, Intercept Pharmaceuticals, Inc., a biopharmaceutical company and Opthotech Corporation, an ophthalmology company. Mr. Sblendorio received his B.B.A. from Pace University, his M.B.A. from Fairleigh Dickinson University, and he is a graduate of Harvard Business School Advanced Management Program.

Jeff Frazier
Executive Vice President

Jeff Frazier joined The Medicines Company (MDCO) in June 2014 as Executive Vice President and Chief Human Strategy Officer. Prior to joining MDCO, Jeff was the Corporate Vice President of Human Resources and Public Affairs at Novo Nordisk Inc. from 2004 to 2014. This leadership translated into Novo Nordisk being named the number one “Best Place to Work” in New Jersey for four out of six years (2004 – 2010), and in being named to the Fortune Magazine "100 Best Companies to Work For" for six consecutive years (2009-2014). Before taking his position at Novo Nordisk, Jeff was head of human resources for Pharmacia Corporation’s Global Pharmaceutical Business unit, where he served as a member of the global commercial leadership team. There he supported international commercial operations of 12,500 employees in 50 countries, through the design and execution of human resources strategy and programs. Prior to that role, he held a number of different senior human resources positions in Europe and in the USA. Jeff received a bachelor’s degree in business administration from Kent State University.

Brent Furse, MBA
Executive Vice President

Brent Furse has been our executive vice president and chief customer officer since March 2014. From August 2011 to March 2014, Mr. Furse served as our senior vice president and chief customer officer and from February 2010 to August 2011, he served as our senior vice president and general manager global commercial operations. Since joining us in July 2000, Mr. Furse has held a variety of roles, including regional sales director, national sales director, vice president of sales, vice president and general manager of interventional and emergency medicine business, vice president of strategic development and vice president of global scientific affairs. Mr. Furse received both a B.A. and an M.B.A. from the Stetson School of Business and Economics at Mercer University.

Nancye Green
Executive Vice President

Nancye Green leads global communications & information architecture for The Medicines Company (MDCO). A designer and business leader, Nancye has had a storied career addressing the complex communication challenges of large enterprises, startup companies and non-profit organizations across industries. She has designed and produced in multiple media on behalf of clients as diverse as Hoffman-La Roche, 3M, P&G, Exxon, the Ronald Reagan Presidential Library, American Express, Sony and American Girl Place, among many others. In addition, Nancye has founded and/or served as CEO of several businesses, including design firm Donovan/Green and Waterworks, and has served on the boards of directors of several companies, including Waterworks and Hallmark. A recognized leader in her field, she is a past president of the American Institute of Graphic Arts and the prestigious International Design Conference in Aspen. She holds degrees from Tulane University and Parsons School of Design, and was awarded an honorary doctorate from The Corcoran School of Art in Washington, D.C.

Cees Heiman, MS
Executive Vice President

Cornelis (Cees) Heiman has been an executive vice president and chief innovation officer since March 2014.  He joined us in June 2012 as our head of the Europe and Middle East business. Mr. Heiman was previously with Pfizer from 1982 until June 2012, where he had most recently served as the regional president of their European Specialty Care Business Unit. Mr. Heiman has broad medical products expertise and extensive international experience and has held leadership positions in marketing, new product development and general management in his native Netherlands as well as India, Hungary, Japan, Poland, Belgium, Italy and Pfizer's New York headquarters. In addition, Mr. Heiman served on numerous boards and organizations representing Pfizer in the external marketplace, including participating in the European Federation of Pharmaceutical Industry Associations (EFPIA) as Pfizer’s head of Europe. Mr. Heiman received a master's degree in pharmacy from the University of Leiden, Netherlands.

Jan Ohrstrom, MD
Senior Vice President

Jan Ohrstrom leads the surgery and hemostasis solutions at The Medicines Company (MDCO) and is managing director for ProFibrix BV, where he was previously CEO and president. Jan has more than 20 years biotech industry experience working for companies in the EU and the US. He started his career at Novo Nordisk A/S in development and marketing roles, and joined the senior management team ZymoGenetics, helping to take the company public. He was responsible for establishing the ZymoGenetics business and development infrastructure, and during his tenure, he submitted the team’s first BLA (RecoThrom©). Jan earned his MD from the University of Copenhagen and completed six years of clinical practice training as a surgeon prior to joining the pharmaceutical industry.

Stephanie Plent, MD
Executive Vice President

Stephanie Plent is the head of global health economics at The Medicines Company (MDCO). Prior to joining MDCO in July 2000, Stephanie worked for healthcare provider Aetna for six years developing cardiac centers of excellence programs in conjunction with major cardiovascular hospitals and launching national disease management programs for asthma, diabetes, heart failure and back pain management. In addition, she was a consultant in the healthcare practice of Arthur D. Little based in Cambridge, Massachusetts. Stephanie received her medical degree from the Royal Free Hospital, London UK and completed her general surgical residency at St. Bartholomew's Hospital in London.

  John Villiger
Executive Vice President

John Villiger is a co-founder of The Medicines Company and was Senior Vice President of Development until February 2006. Since November 2006 John has been a member of the Pharmaxis Board of Directors. John is also executive chairman of Proacta Inc. From 1986 to 1996 John held various positions in product development at Roche in both New Zealand and Switzerland, including International Project Director from 1991 to 1995 and Head of Global Project Management from 1995 to 1996. As Head of Global Project Management, he oversaw the development of Roche’s pharmaceutical portfolio, with programs in Switzerland, the UK, US and Japan. John holds a Ph.D. in psychopharmacology from the University of Otago. He is also a member of the Remuneration and Nomination Committee.